nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—autistic disorder	0.472	1	CbGaD
Thalidomide—NFKB1—mouth—autistic disorder	0.0105	0.0615	CbGeAlD
Thalidomide—FGFR2—hindbrain—autistic disorder	0.009	0.0527	CbGeAlD
Thalidomide—FGFR2—mouth—autistic disorder	0.00789	0.0462	CbGeAlD
Thalidomide—NFKB1—eye—autistic disorder	0.00668	0.0391	CbGeAlD
Thalidomide—NFKB1—forebrain—autistic disorder	0.00663	0.0388	CbGeAlD
Thalidomide—NFKB1—telencephalon—autistic disorder	0.00609	0.0357	CbGeAlD
Thalidomide—CRBN—forebrain—autistic disorder	0.00555	0.0325	CbGeAlD
Thalidomide—FGFR2—brainstem—autistic disorder	0.00516	0.0302	CbGeAlD
Thalidomide—CRBN—telencephalon—autistic disorder	0.00511	0.0299	CbGeAlD
Thalidomide—FGFR2—eye—autistic disorder	0.00502	0.0294	CbGeAlD
Thalidomide—FGFR2—forebrain—autistic disorder	0.00498	0.0291	CbGeAlD
Thalidomide—NFKB1—digestive system—autistic disorder	0.00465	0.0272	CbGeAlD
Thalidomide—FGFR2—telencephalon—autistic disorder	0.00458	0.0268	CbGeAlD
Thalidomide—CRBN—digestive system—autistic disorder	0.0039	0.0228	CbGeAlD
Thalidomide—Menadione—XDH—autistic disorder	0.00388	0.305	CrCbGaD
Thalidomide—NFKB1—head—autistic disorder	0.00379	0.0222	CbGeAlD
Thalidomide—NFKB1—nervous system—autistic disorder	0.0036	0.0211	CbGeAlD
Thalidomide—FGFR2—digestive system—autistic disorder	0.00349	0.0204	CbGeAlD
Thalidomide—NFKB1—central nervous system—autistic disorder	0.00346	0.0203	CbGeAlD
Thalidomide—NFKB1—cerebellum—autistic disorder	0.00338	0.0198	CbGeAlD
Thalidomide—CRBN—head—autistic disorder	0.00318	0.0186	CbGeAlD
Thalidomide—Menadione—MAOB—autistic disorder	0.00303	0.238	CrCbGaD
Thalidomide—CRBN—nervous system—autistic disorder	0.00301	0.0176	CbGeAlD
Thalidomide—CRBN—central nervous system—autistic disorder	0.0029	0.017	CbGeAlD
Thalidomide—CYP1A1—mouth—autistic disorder	0.00286	0.0167	CbGeAlD
Thalidomide—FGFR2—head—autistic disorder	0.00285	0.0167	CbGeAlD
Thalidomide—CRBN—cerebellum—autistic disorder	0.00284	0.0166	CbGeAlD
Thalidomide—NFKB1—brain—autistic disorder	0.00275	0.0161	CbGeAlD
Thalidomide—FGFR2—nervous system—autistic disorder	0.0027	0.0158	CbGeAlD
Thalidomide—FGFR2—central nervous system—autistic disorder	0.0026	0.0152	CbGeAlD
Thalidomide—FGFR2—cerebellum—autistic disorder	0.00254	0.0149	CbGeAlD
Thalidomide—PTGS2—mouth—autistic disorder	0.0024	0.014	CbGeAlD
Thalidomide—CRBN—brain—autistic disorder	0.0023	0.0135	CbGeAlD
Thalidomide—Menadione—MTHFR—autistic disorder	0.00216	0.17	CrCbGaD
Thalidomide—FGFR2—brain—autistic disorder	0.00206	0.0121	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—autistic disorder	0.0019	0.149	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—autistic disorder	0.00176	0.138	CrCbGaD
Thalidomide—PTGS1—forebrain—autistic disorder	0.00158	0.00926	CbGeAlD
Thalidomide—CYP2C19—digestive system—autistic disorder	0.00157	0.00918	CbGeAlD
Thalidomide—PTGS2—forebrain—autistic disorder	0.00151	0.00885	CbGeAlD
Thalidomide—CYP2E1—telencephalon—autistic disorder	0.00151	0.00884	CbGeAlD
Thalidomide—PTGS1—telencephalon—autistic disorder	0.00145	0.00852	CbGeAlD
Thalidomide—PTGS2—telencephalon—autistic disorder	0.00139	0.00814	CbGeAlD
Thalidomide—CYP1A2—digestive system—autistic disorder	0.00128	0.0075	CbGeAlD
Thalidomide—CYP1A1—digestive system—autistic disorder	0.00126	0.0074	CbGeAlD
Thalidomide—CYP3A5—digestive system—autistic disorder	0.00124	0.00723	CbGeAlD
Thalidomide—CYP2C9—digestive system—autistic disorder	0.00122	0.00712	CbGeAlD
Thalidomide—CYP2E1—digestive system—autistic disorder	0.00115	0.00675	CbGeAlD
Thalidomide—PTGS1—digestive system—autistic disorder	0.00111	0.0065	CbGeAlD
Thalidomide—PTGS2—digestive system—autistic disorder	0.00106	0.00621	CbGeAlD
Thalidomide—CYP1A1—head—autistic disorder	0.00103	0.00604	CbGeAlD
Thalidomide—CYP1A1—nervous system—autistic disorder	0.000978	0.00572	CbGeAlD
Thalidomide—CYP1A1—central nervous system—autistic disorder	0.000941	0.00551	CbGeAlD
Thalidomide—CYP2E1—head—autistic disorder	0.00094	0.0055	CbGeAlD
Thalidomide—PTGS1—head—autistic disorder	0.000906	0.0053	CbGeAlD
Thalidomide—CYP2E1—nervous system—autistic disorder	0.000892	0.00522	CbGeAlD
Thalidomide—PTGS2—head—autistic disorder	0.000866	0.00507	CbGeAlD
Thalidomide—PTGS1—nervous system—autistic disorder	0.000859	0.00503	CbGeAlD
Thalidomide—CYP2E1—central nervous system—autistic disorder	0.000858	0.00502	CbGeAlD
Thalidomide—CYP2E1—cerebellum—autistic disorder	0.000839	0.00491	CbGeAlD
Thalidomide—PTGS1—central nervous system—autistic disorder	0.000827	0.00484	CbGeAlD
Thalidomide—PTGS2—nervous system—autistic disorder	0.000821	0.0048	CbGeAlD
Thalidomide—PTGS2—central nervous system—autistic disorder	0.00079	0.00463	CbGeAlD
Thalidomide—PTGS2—cerebellum—autistic disorder	0.000773	0.00452	CbGeAlD
Thalidomide—CYP1A1—brain—autistic disorder	0.000747	0.00437	CbGeAlD
Thalidomide—CYP2E1—brain—autistic disorder	0.000681	0.00399	CbGeAlD
Thalidomide—PTGS1—brain—autistic disorder	0.000656	0.00384	CbGeAlD
Thalidomide—PTGS2—brain—autistic disorder	0.000627	0.00367	CbGeAlD
Thalidomide—TNF—Developmental Biology—MAPK1—autistic disorder	2.69e-05	7.82e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—autistic disorder	2.68e-05	7.77e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALCA—autistic disorder	2.67e-05	7.77e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPH2—autistic disorder	2.65e-05	7.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ITGB3—autistic disorder	2.65e-05	7.69e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	2.64e-05	7.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—autistic disorder	2.63e-05	7.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TCN2—autistic disorder	2.61e-05	7.59e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DPYD—autistic disorder	2.61e-05	7.59e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—autistic disorder	2.6e-05	7.56e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—autistic disorder	2.59e-05	7.52e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNA1C—autistic disorder	2.58e-05	7.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—autistic disorder	2.57e-05	7.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNA1C—autistic disorder	2.57e-05	7.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2—autistic disorder	2.56e-05	7.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—autistic disorder	2.54e-05	7.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—autistic disorder	2.51e-05	7.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RORA—autistic disorder	2.49e-05	7.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADA—autistic disorder	2.49e-05	7.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DHFR—autistic disorder	2.49e-05	7.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—autistic disorder	2.48e-05	7.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSC2—autistic disorder	2.47e-05	7.18e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—autistic disorder	2.47e-05	7.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—autistic disorder	2.46e-05	7.16e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—autistic disorder	2.46e-05	7.13e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	2.45e-05	7.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNA1C—autistic disorder	2.43e-05	7.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—autistic disorder	2.42e-05	7.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—autistic disorder	2.42e-05	7.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—autistic disorder	2.41e-05	6.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADSL—autistic disorder	2.4e-05	6.98e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—autistic disorder	2.4e-05	6.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—autistic disorder	2.38e-05	6.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—autistic disorder	2.38e-05	6.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRL—autistic disorder	2.36e-05	6.86e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—autistic disorder	2.36e-05	6.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—XDH—autistic disorder	2.36e-05	6.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSC2—autistic disorder	2.35e-05	6.82e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DHFR—autistic disorder	2.34e-05	6.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DHFR—autistic disorder	2.34e-05	6.79e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOB—autistic disorder	2.34e-05	6.79e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—autistic disorder	2.33e-05	6.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—STX1A—autistic disorder	2.31e-05	6.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NPAS2—autistic disorder	2.31e-05	6.72e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	2.3e-05	6.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—autistic disorder	2.3e-05	6.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—autistic disorder	2.3e-05	6.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—autistic disorder	2.28e-05	6.63e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—COMT—autistic disorder	2.28e-05	6.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRKCB—autistic disorder	2.28e-05	6.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—autistic disorder	2.28e-05	6.61e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RORA—autistic disorder	2.27e-05	6.6e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—autistic disorder	2.27e-05	6.6e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—autistic disorder	2.27e-05	6.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—autistic disorder	2.26e-05	6.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—autistic disorder	2.25e-05	6.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—autistic disorder	2.24e-05	6.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TCN2—autistic disorder	2.23e-05	6.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—autistic disorder	2.22e-05	6.46e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAT—autistic disorder	2.21e-05	6.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DHFR—autistic disorder	2.21e-05	6.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APC—autistic disorder	2.18e-05	6.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CG—autistic disorder	2.18e-05	6.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH2—autistic disorder	2.17e-05	6.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRKCB—autistic disorder	2.17e-05	6.29e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—autistic disorder	2.16e-05	6.28e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGF—autistic disorder	2.16e-05	6.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—autistic disorder	2.14e-05	6.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADA—autistic disorder	2.13e-05	6.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOB—autistic disorder	2.13e-05	6.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—autistic disorder	2.12e-05	6.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—autistic disorder	2.11e-05	6.12e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G4A—autistic disorder	2.09e-05	6.06e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—autistic disorder	2.09e-05	6.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—autistic disorder	2.08e-05	6.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APC—autistic disorder	2.07e-05	6.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CG—autistic disorder	2.07e-05	6.02e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—autistic disorder	2.07e-05	6.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGF—autistic disorder	2.05e-05	5.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—autistic disorder	2.03e-05	5.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—autistic disorder	2.02e-05	5.86e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	2.01e-05	5.83e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—autistic disorder	2e-05	5.81e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX1—autistic disorder	2e-05	5.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNA1C—autistic disorder	1.99e-05	5.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH2—autistic disorder	1.98e-05	5.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—autistic disorder	1.97e-05	5.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—autistic disorder	1.96e-05	5.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—autistic disorder	1.95e-05	5.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—autistic disorder	1.95e-05	5.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RORA—autistic disorder	1.94e-05	5.64e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—autistic disorder	1.91e-05	5.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—autistic disorder	1.9e-05	5.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—autistic disorder	1.9e-05	5.51e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	1.86e-05	5.41e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—autistic disorder	1.85e-05	5.36e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—autistic disorder	1.83e-05	5.33e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—autistic disorder	1.83e-05	5.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	1.83e-05	5.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	1.83e-05	5.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOB—autistic disorder	1.82e-05	5.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK1—autistic disorder	1.82e-05	5.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—COMT—autistic disorder	1.81e-05	5.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNA1C—autistic disorder	1.81e-05	5.26e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DHFR—autistic disorder	1.81e-05	5.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—autistic disorder	1.8e-05	5.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—autistic disorder	1.8e-05	5.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—autistic disorder	1.8e-05	5.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAT—autistic disorder	1.76e-05	5.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—autistic disorder	1.75e-05	5.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—autistic disorder	1.74e-05	5.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—autistic disorder	1.74e-05	5.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—autistic disorder	1.73e-05	5.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—autistic disorder	1.73e-05	5.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—autistic disorder	1.73e-05	5.01e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—autistic disorder	1.72e-05	4.99e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—COMT—autistic disorder	1.71e-05	4.96e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COMT—autistic disorder	1.7e-05	4.95e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—autistic disorder	1.7e-05	4.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—autistic disorder	1.69e-05	4.92e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—autistic disorder	1.69e-05	4.92e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH2—autistic disorder	1.69e-05	4.92e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—autistic disorder	1.69e-05	4.91e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—autistic disorder	1.67e-05	4.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TSC2—autistic disorder	1.66e-05	4.83e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—autistic disorder	1.66e-05	4.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G4A—autistic disorder	1.66e-05	4.81e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—autistic disorder	1.65e-05	4.8e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—autistic disorder	1.65e-05	4.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DHFR—autistic disorder	1.65e-05	4.79e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—autistic disorder	1.63e-05	4.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	1.62e-05	4.72e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COMT—autistic disorder	1.61e-05	4.67e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—autistic disorder	1.6e-05	4.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—autistic disorder	1.6e-05	4.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—autistic disorder	1.59e-05	4.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—autistic disorder	1.59e-05	4.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—autistic disorder	1.56e-05	4.54e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G4A—autistic disorder	1.56e-05	4.53e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—autistic disorder	1.56e-05	4.53e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—autistic disorder	1.56e-05	4.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G4A—autistic disorder	1.56e-05	4.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—autistic disorder	1.56e-05	4.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—autistic disorder	1.55e-05	4.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1C—autistic disorder	1.55e-05	4.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—autistic disorder	1.54e-05	4.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	1.52e-05	4.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—autistic disorder	1.52e-05	4.41e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—autistic disorder	1.49e-05	4.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—autistic disorder	1.49e-05	4.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—autistic disorder	1.49e-05	4.32e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—autistic disorder	1.48e-05	4.29e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4A—autistic disorder	1.47e-05	4.27e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—autistic disorder	1.47e-05	4.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—autistic disorder	1.47e-05	4.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—autistic disorder	1.46e-05	4.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—autistic disorder	1.46e-05	4.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—autistic disorder	1.46e-05	4.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGF—autistic disorder	1.45e-05	4.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—autistic disorder	1.45e-05	4.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—autistic disorder	1.42e-05	4.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—autistic disorder	1.41e-05	4.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DHFR—autistic disorder	1.41e-05	4.09e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—autistic disorder	1.4e-05	4.06e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	1.39e-05	4.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—autistic disorder	1.39e-05	4.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—autistic disorder	1.38e-05	4.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—autistic disorder	1.38e-05	4e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—autistic disorder	1.37e-05	3.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—autistic disorder	1.36e-05	3.96e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	1.33e-05	3.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—autistic disorder	1.33e-05	3.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—autistic disorder	1.32e-05	3.82e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—autistic disorder	1.31e-05	3.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—autistic disorder	1.31e-05	3.8e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—autistic disorder	1.3e-05	3.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—autistic disorder	1.29e-05	3.75e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—autistic disorder	1.28e-05	3.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—autistic disorder	1.28e-05	3.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—autistic disorder	1.28e-05	3.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—autistic disorder	1.28e-05	3.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—autistic disorder	1.27e-05	3.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—autistic disorder	1.23e-05	3.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—autistic disorder	1.22e-05	3.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	1.21e-05	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—autistic disorder	1.21e-05	3.52e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4A—autistic disorder	1.2e-05	3.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—autistic disorder	1.2e-05	3.5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—autistic disorder	1.2e-05	3.49e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—autistic disorder	1.19e-05	3.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—autistic disorder	1.19e-05	3.46e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—autistic disorder	1.19e-05	3.45e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—autistic disorder	1.18e-05	3.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—autistic disorder	1.18e-05	3.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—autistic disorder	1.17e-05	3.4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—autistic disorder	1.16e-05	3.38e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—autistic disorder	1.16e-05	3.37e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—autistic disorder	1.16e-05	3.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—autistic disorder	1.15e-05	3.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—autistic disorder	1.12e-05	3.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—autistic disorder	1.1e-05	3.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—autistic disorder	1.1e-05	3.2e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—autistic disorder	1.1e-05	3.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4A—autistic disorder	1.1e-05	3.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—autistic disorder	1.1e-05	3.19e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—autistic disorder	1.09e-05	3.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—autistic disorder	1.06e-05	3.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—autistic disorder	1.05e-05	3.05e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—autistic disorder	1.04e-05	3.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—autistic disorder	1.04e-05	3.01e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—autistic disorder	1.03e-05	2.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—autistic disorder	1.03e-05	2.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—autistic disorder	1.02e-05	2.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—autistic disorder	1.02e-05	2.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—autistic disorder	9.93e-06	2.89e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—autistic disorder	9.9e-06	2.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—autistic disorder	9.73e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—autistic disorder	9.7e-06	2.82e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—autistic disorder	9.44e-06	2.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—autistic disorder	9.38e-06	2.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4A—autistic disorder	9.38e-06	2.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—autistic disorder	9.03e-06	2.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—autistic disorder	9.03e-06	2.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—autistic disorder	8.98e-06	2.61e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—autistic disorder	8.96e-06	2.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—autistic disorder	8.94e-06	2.6e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—autistic disorder	8.8e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—autistic disorder	8.78e-06	2.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—autistic disorder	8.57e-06	2.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—autistic disorder	8.51e-06	2.47e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—autistic disorder	8.29e-06	2.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—autistic disorder	8.29e-06	2.41e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—autistic disorder	8.15e-06	2.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—autistic disorder	8.15e-06	2.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—autistic disorder	7.91e-06	2.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—autistic disorder	7.76e-06	2.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—autistic disorder	7.72e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—autistic disorder	7.67e-06	2.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—autistic disorder	7.66e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—autistic disorder	7.23e-06	2.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—autistic disorder	6.96e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—autistic disorder	6.79e-06	1.97e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—autistic disorder	6.63e-06	1.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—autistic disorder	6.35e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—autistic disorder	6.19e-06	1.8e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—autistic disorder	6.08e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—autistic disorder	5.92e-06	1.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—autistic disorder	5.4e-06	1.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—autistic disorder	5.29e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—autistic disorder	4.61e-06	1.34e-05	CbGpPWpGaD
